The NCI played an early role in the development of anti-cancer drugs in the U.S. According to a 1996 NCI analysis of drugs approved by the FDA, two-thirds of the anti-cancer drugs approved as of the end of 1995 were NCI-sponsored Investigational New Drugs:
Alkylating agents
Cyclophosphamide.
.
Chlorambucil (Leukeran) (1957)
Cyclophosphamide (Cytoxan) (1959)
Thiotepa (1959)
Melphalan (Alkeran) (1959) (IV in 1993)
Streptozotocin (Zanosar) (1982)
Ifosfamide (Ifex) (1988)
Antimetabolites
Mercaptopurine (1953)
Methotrexate (1953)
Thioguanine (1966)
Cytosine arabinoside (Ara-C) (1969)
Floxuridine (FUDR) (1970)
Fludarabine phosphate (1991)
Pentostatin (1991)
Chlorodeoxyadenosine (1992)
Plant alkaloids and antibiotics
Vincristine.
Vincristine (Oncovin) (1963)
Actinomycin D (Cosmegen) (1964)
Mithramycin (Mithracin) (1970)
Bleomycin (Blenoxane) (1973)
Doxorubicin (Adriamycin) (1974)
Mitomycin C (Mutamycin) (1974)
L-Asparaginase (Elspar) (1978)
Daunomycin (Cerubidine) (1979)
VP-16-213 (Etoposide) (1983)
VM-26 (Teniposide) (1992)
Taxol (Paclitaxel) (1992)
Synthetic drugs
Carboplatin.
Hydroxyurea (Hydrea) (1967)
Procarbazine (Matulane) (1969)
O, P'-DDD (Lysodren, Mitotane) (1970)
Dacarbazine (DTIC) (1975)
CCNU (Lomustine) (1976)
BCNU (Carmustine) (1977)
Cis-diamminedichloroplatinum (Cisplatin) (1978)
Mitoxantrone (Novantrone) (1988)
Carboplatin (Paraplatin) (1989)
Levamisole (Ergamisol) (1990)
Hexamethylmelamine (Hexalen) (1990)
All-trans retinoid acid (Vesanoid) (1995)
Porfimer sodium (Photofrin) (1995)
Hormones and steroids
DES (1950)
Prednisone (1953)
Fluoxymesterone (Halotestin) (1958)
Dromostanolone (Drolban) (1961)
Testolactone (Teslac) (1970)
Methyl prednisolone
Prednisolone
Zoladex (1989)
Biologicals
Alpha interferon (Intron A, Roferon-A) (1986)
BCG (TheraCys, TICE) (1990)
G-CSF (1991)
GM-CSF (1991)
Interleukin 2 (Proleukin) (1992)
In addition, scientists in the NCI played an important role in the discovery and development of important AIDS drugs including zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC).
From Wikipedia, the free encyclopedia
Last updated: 20/07/2009 14:02MediaPharma s.r.l. P.IVA.: IT 02282760699 | Rea di Chieti: 166532
The information provided on www.mediapharma.it is designed to complement, not replace, the relationship between a patient and his/her own physician.